GENEVA, Switzerland, June 29 /PRNewswire/ --

- Pergoveris(TM) is the Only Infertility Treatment to Offer the Benefits
of Recombinant Human FSH and LH in a Single Injection

Merck Serono S.A. (virt-x: SEO) announced today that the
European Commission has granted a marketing authorization for Pergoveris(TM)
intended for the stimulation of follicular development in women with severe
luteinizing hormone (LH) and follicle stimulating hormone (FSH) deficiency.
Pergoveris(TM) is the first biotechnology product based on the combination of
recombinant human FSH (r-hFSH or follitropin alfa 150IU) and recombinant
human LH (r-hLH or lutropin alfa 75IU), which allows administration of both
substances in a single subcutaneous injection.

"The European Commission approval of Pergoveris(TM) is good
news for infertile women in Europe who have severe endogenous FSH and LH
deficiencies," said Hans Christian Rohde, Head of Global Therapeutic Area
Reproductive Health, Merck Serono. "Pergoveris(TM) is the only fertility
treatment which combines the benefits of two consistent and pure recombinant
products - r-hFSH and r-hLH. The development of Pergoveris(TM) shows our
innovative leadership in fertility treatments and ability to provide pure and
high quality products".

The European Commission decision applies to all 27 countries
in the European Union(1), as well as Iceland, Liechtenstein and Norway.
Launches of Pergoveris(TM) in the various countries of the European Union
will start in the third quarter of 2007.

(1) Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, The Republic of Ireland, Italy,
Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, United Kingdom

Merck Serono and Fertility Treatment

Merck Serono, the world leader in reproductive health, is
dedicated to providing patient-friendly, innovative products to help couples
build families. Merck Serono is the only company to offer a full portfolio of
fertility drugs for every stage of the reproductive cycle and recombinant
versions of the three hormones needed to treat infertility: GONAL-f(r) FbM
(follitropin alfa), to stimulate the ovaries and produce eggs; Luveris(R)
(lutropin alfa), to stimulate follicular development in women who are
profoundly LH deficient; Cetrotide(R) (cetrorelix acetate) to prevent a
premature ovulation; Ovitrelle(R) (choriogonadotropin alfa), to help
follicles mature and release eggs; and Crinone(R) (progesterone gel), to help
establish and maintain a pregnancy.

Forward-looking statements

Some of the statements in this press release are forward
looking. Such statements are inherently subject to known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements of Merck Serono S.A. and affiliates to be materially different
from those expected or anticipated in the forward-looking statements.
Forward-looking statements are based on Merck Serono's current expectations
and assumptions, which may be affected by a number of factors, including
those discussed in this press release and more fully described in Serono's
Annual Report on Form 20-F filed with the U.S. Securities and Exchange
Commission on February 28, 2006. These factors include any failure or delay
in Merck Serono's ability to develop new products, any failure to receive
anticipated regulatory approvals, any problems in commercializing current
products as a result of competition or other factors, our ability to obtain
reimbursement coverage for our products, the outcome of any government
investigations and litigation. Merck Serono is providing this information as
of the date of this press release, and has no responsibility to update the
forward-looking statements contained in this press release to reflect events
or circumstances occurring after the date of this press release.

About Merck Serono S.A.

Merck Serono S.A. is a global biotechnology leader, with sales
in over 90 countries. The Company is the world leader in reproductive health,
with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market
positions in neurology, with Rebif(R), as well as in metabolism and growth,
with Saizen(R), Serostim(R) and Zorbtive(TM). The Company has recently
entered the psoriasis area with Raptiva(R). Merck Serono's research programs
are focused on growing these businesses and on establishing new therapeutic
areas, including oncology and autoimmune diseases.

Bearer shares of Merck Serono S.A., the holding company, are
traded on the virt-x (SEO).

About Merck

Merck is a global pharmaceutical and chemical company with sales of EUR
6.3 billion in 2006, a history that began in 1668, and a future shaped by
35,091 employees in 62 countries. Its success is characterized by innovations
from entrepreneurial employees. Merck's operating activities come under the
umbrella of Merck KGaA, in which the Merck family holds an approximately 70%
interest and free shareholders own the remaining approximately 30%. In 1917
the U.S. subsidiary Merck & Co. was expropriated and has been an independent
company ever since.

www.merckserono.net